22:16 , Aug 16, 2019 |  BioCentury  |  Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life...
18:26 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Bolt's immune-stimulating antibody conjugates decrease tumor growth

Bolt said TLR agonist antibody conjugates from its Immune-Stimulating Antibody Conjugate (ISAC) platform led to immune activation and tumor clearance in preclinical cancer models. In a presentation at the American Association for Cancer Research (AACR)...
15:45 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Bolt raises $54M series B

Autoimmune company Bolt Biotherapeutics Inc. (Redwood City, Calif.) raised $54 million in a series B round led by Pivotal bioVenture Partners. Nan Fung Life Sciences along with existing investors Novo Holdings and Vivo Ventures also...